Ad
Adlai Nortye
Hangzhou CNFounded 2016200 employees
Private CapbiotechPrivateOncology
Platform: AN2025 BC
Market Cap
N/A
All Drugs
2
Clinical Trials
2
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Polazumab | ADL-3178 | Phase 3 | 1 | KRASG12D | CRCIgAN | ||
| Gozerapivir | ADL-4201 | Phase 2 | 1 | CD38 | EoETTR Amyloidosis |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (2)